Christopher Kerfoot, Ph.D., Co-founder, Managing Member
Dr. Kerfoot is co-founder of Mosaic Laboratories and has an established track record in oncology research, clinical testing and product development. Dr. Kerfoot has developed methods, reagents and image analysis methods for multiplex immunohistochemistry and had a leading role in multispectral imaging of chromogenic stains. Previously, Dr. Kerfoot served as Director of Product Development at US Labs, Director of Pharmaceutical Services at Oncotech, and Director of Molecular Oncology at IMPATH.
These efforts have led to patent applications, the development of many diagnostic assays as well as added value to experimental therapeutics. His broad-based expertise in assay development includes immunohistochemistry, chemosensitivity testing, in situ hybridization, flow cytometry, quantitative PCR, and other proteomic and molecular techniques. Dr. Kerfoot has published numerous peer-reviewed articles, abstracts and other publications in the areas of chemosensitivity, molecular and immunohistochemical testing. Dr. Kerfoot received his doctoral degree in Experimental Pathology in the Department of Pathology and Laboratory Medicine at UCLA. He was awarded fellowships from Leslie and Susan Gonda and The National Institute for Global Environmental Change. He received his B.S. in chemistry at the University of Illinois – Champaign/Urbana. His professional memberships include the American Association for Cancer Research and American Society of Clinical Oncology.
Lisa Dauffenbach, M.S., Co-founder, Managing Member
Ms. Dauffenbach is a co-founder of Mosaic Laboratories and has an established track record in oncology research and implementing efficient and profitable laboratory operations. Ms. Dauffenbach developed the Mosaic Blue assay for in vitro chemosensitivity testing of solid tumor explants, a method that is used to evaluate novel chemotherapeutic agents for activity prior to conducting clinical trials.
She has directed pre-clinical and clinical trial laboratory studies on Treanda, Tykerb, Tarceva, Iressa, VX-944, XAA296, EPO906, ispinesib, aurora inhibitors, c-Met inhibitors, and numerous other compounds. Previously, Ms. Dauffenbach served as Senior Scientist for Oncotech. Her post-doctoral training in the Departments of OBGYN and Pharmacology at the University of Minnesota involved extensive research in the areas of signal transduction and apoptosis, protein mass production and purification, animal modeling, whole cell assays, and transcriptomics. Ms. Dauffenbach received her master’s degree in biomedical engineering at Iowa State University. Ms. Dauffenbach has published numerous peer-reviewed articles and abstracts in the areas of chemosensitivity, apoptosis, immunohistochemistry, molecular genetics and robotics. She received her B.S. in chemistry at the University of Minnesota. Her professional memberships include the American Association for Cancer Research and American Society of Clinical Oncology.